Comparasion of Autogenic Inhibition and Reciprocal Inhibition Muscle Energy Techniques (METS) in Piriformis Syndrome

June 11, 2024 updated by: Riphah International University

Comparative Effects of Autogenic Inhibition and Reciprocal Inhibition Muscle Energy Techniques in Piriformis Syndrome

To compare the effects of Autogenic Inhibition and Reciprocal Inhibition Muscle Energy Techniques (METS) in Piriformis Syndrome

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Piriformis syndrome is when the piriformis muscle, located in the buttock region, spasms and causes buttock pain. The piriformis muscle also can irritate the nearby sciatic nerve and cause pain, numbness, and tingling along the back of the leg and into the foot (similar to sciatic pain). The functional limitations experienced by hip pain patients in the lower limb profoundly impact their quality of life. This study aims to investigate the effectiveness of an integrated approach that compares the Effects of Autogenic Inhibition versus Reciprocal Inhibition Muscle Energy Techniques on Pain, Range of motion, and Disability in patients with Piriformis Syndrome.

This randomized clinical trial will be conducted at DHQ Hospital Jhang over six months. The sample size will consist of 32 participants. Participants who meet the inclusion criteria will be taken through a non-probability convenience sampling technique, that will be randomized through a sealed envelope method. 16 Participants will be assigned to Group A that will be treated with the Autogenic Inhibition Muscle Energy Technique, 16 Participants will be assigned to Group B and will be treated with Reciprocal Inhibition Muscle Energy Technique at the frequency of 1 set and 3 repetitions per session for two sessions per week and total six sessions for three weeks with follow up at one month. The duration of contraction is 7-10 seconds. Pre and post-intervention values will be taken on the 1st day in the 3rd week and at one-month follow-up. Data will be collected using various assessment tools, including the FAIR test, Freiberg test, Lasegue test, Beatty test, Pace sign, Numeric Pain Rating Scale (NPRS), and Universal Goniometer. Pre-intervention assessments will be conducted for all two groups. The effects of the interventions will be measured either by parametric or non-parametric tests after assessing the normality of data by the Shapiro-Wilk test Independent t-test. Data analysis will be performed by using SPSS 25 software.

Study Type

Interventional

Enrollment (Estimated)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Pakistan
    • Punjab
      • Rawalpindi, Punjab, Pakistan, 46000
        • Recruiting
        • IIMCT Railway General Hospital
        • Contact:
        • Principal Investigator:
          • Mateen Asghar, MS(OMPT)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Both genders with ages between 25-45 years.
  • Patients diagnosed with Piriformis syndrome using the Piriformis FAIR test, Freiberg test, Lasegue test, Beaty test, and pace sign.
  • Hip pain with a threshold of NPRS 3-6.
  • Limited ROM of Hip Internal Rotation and Abduction measured using a goniometer.
  • Buttock pain ≥ 3 months.
  • Pain with prolonged sitting (more than 20 minutes)

Exclusion Criteria:

  • Hip Degenerative changes.
  • History of Trauma or Fracture
  • Other Systemic Conditions
  • Postural abnormality/deformity
  • Diagnosed Psychological Disorders
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Autogenic Inhibition Muscle Energy Technique
This group will receive Autogenic Inhibition Muscle Energy Technique
Procedure: Autogenic Inhibition Muscle Energy Technique
No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per weeks for 3 weeks (40 Min per Session)
Procedure: Reciprocal Inhibition Muscle Energy Technique
No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per week for 3 weeks (40 Min per Session)
Active Comparator: Reciprocal Inhibition Muscle Energy Technique
This group will receive Reciprocal Inhibition Muscle Energy Technique
Procedure: Autogenic Inhibition Muscle Energy Technique
No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per weeks for 3 weeks (40 Min per Session)
Procedure: Reciprocal Inhibition Muscle Energy Technique
No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per week for 3 weeks (40 Min per Session)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain : Numeric Pain Rating Scale (NPRS)
Time Frame: 3 Weeks
Patients' overall assessment of pain will be provided using the numeric pain rating scale
3 Weeks
Range of Motion : Universal Goniometer
Time Frame: 3 Weeks
It is frequently employed as a benchmark technique for the assessment of Range of Motion
3 Weeks
Lower Extremity Functional Scale (LEFS)
Time Frame: 3 Weeks
The LEFS is a self-report questionnaire intended to assess functional status in patients with disability of the lower extremity (e.g., hip, thigh, ankle) containing 20 questions about a person's ability to perform everyday tasks
3 Weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Riphah International University

Investigators

  • Principal Investigator: Rabiya Noor, PhD, Riphah International University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2024

Primary Completion (Estimated)

October 10, 2024

Study Completion (Estimated)

November 10, 2024

Study Registration Dates

First Submitted

June 11, 2024

First Submitted That Met QC Criteria

June 11, 2024

First Posted (Actual)

June 14, 2024

Study Record Updates

Last Update Posted (Actual)

June 14, 2024

Last Update Submitted That Met QC Criteria

June 11, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • REC/RCR & AHS/23/01114

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Piriformis Syndrome

Clinical Trials on Autogenic Inhibition Muscle Energy Technique

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe